Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
72 hedge funds and large institutions have $1.01B invested in Kronos Bio in 2020 Q4 according to their latest regulatory filings, with 72 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
60.89% more ownership
Funds ownership: 0% → 60.89% (+61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$120M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$111M |
| 3 |
PA
Perceptive Advisors
New York
|
+$87.2M |
| 4 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
+$86.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$80.6M |
Top Sellers
KRON Hedge Fund Activity: Q4 2020 in Review
72 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q4 2020, worth a combined $1.01B.
Buyers outnumbered sellers: 72 funds opened new KRON positions and 0 closed out — a net gain of 72 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Omega Fund Management, opening a new position worth an estimated $120M.
- 72 institutional investors held Kronos Bio (KRON) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $1.01B of Kronos Bio stock for Q4 2020.
- 72 funds opened new Kronos Bio positions in Q4 2020 and 0 closed out, a net change of +72 holders.
- The largest Kronos Bio buyer in Q4 2020 was Omega Fund Management, an estimated $120M added.
Based on aggregated 13F filings for Q4 2020.